CA2137784A1 - Temoin renfermant un marqueur tumoral - Google Patents

Temoin renfermant un marqueur tumoral

Info

Publication number
CA2137784A1
CA2137784A1 CA002137784A CA2137784A CA2137784A1 CA 2137784 A1 CA2137784 A1 CA 2137784A1 CA 002137784 A CA002137784 A CA 002137784A CA 2137784 A CA2137784 A CA 2137784A CA 2137784 A1 CA2137784 A1 CA 2137784A1
Authority
CA
Canada
Prior art keywords
serum
tumor
markers
cea
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002137784A
Other languages
English (en)
Inventor
Kathryn Herring
Denise Sandberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dade International Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2137784A1 publication Critical patent/CA2137784A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/665—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • G01N2333/695—Corticotropin [ACTH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002137784A 1993-04-22 1994-04-08 Temoin renfermant un marqueur tumoral Abandoned CA2137784A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5200193A 1993-04-22 1993-04-22
US08/052,001 1993-04-22

Publications (1)

Publication Number Publication Date
CA2137784A1 true CA2137784A1 (fr) 1994-10-27

Family

ID=21974763

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002137784A Abandoned CA2137784A1 (fr) 1993-04-22 1994-04-08 Temoin renfermant un marqueur tumoral

Country Status (5)

Country Link
EP (1) EP0647322A1 (fr)
JP (1) JPH07508352A (fr)
AU (1) AU679743B2 (fr)
CA (1) CA2137784A1 (fr)
WO (1) WO1994024569A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1166957A (fr) * 1980-05-08 1984-05-08 Barry I. Bluestein Dosage immunologique d'un antigene oncofoetal porte par les lymphocytes
US4489167A (en) * 1981-06-02 1984-12-18 Baxter Travenol Laboratories, Inc. Methods and compositions for cancer detection
US4994375A (en) * 1988-07-11 1991-02-19 Baxter International Inc. Stable human serum based control and/or calibrant
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
US5296346A (en) * 1990-11-19 1994-03-22 Nonda Katopodis Method for determining lipid bound sialic acid in plasma

Also Published As

Publication number Publication date
EP0647322A1 (fr) 1995-04-12
WO1994024569A1 (fr) 1994-10-27
AU6629294A (en) 1994-11-08
AU679743B2 (en) 1997-07-10
JPH07508352A (ja) 1995-09-14

Similar Documents

Publication Publication Date Title
Jones et al. Serum ferritin in patients with cancer: determination with antibodies to HeLa cell and spleen ferritin
US5747268A (en) Tumor marker control
Rosen et al. Human fibroblasts produce “pregnancy-specific” beta-1 glycoprotein in vitro
US4486538A (en) Detection of malignant tumor cells
US4554256A (en) Antigen associated with early detection of mammalian pregnancy
CA1177750A (fr) Dosage de l'adenosine
Kinoshita et al. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1).
US4725557A (en) Production of fucosyl antigens and antibodies for recognizing same determination of cancer associated carbohydrate linkage using same and kit for the determination
JPH0354679B2 (fr)
Todd et al. Serum levels of fibronectin and a fibronectin-like DNA-binding protein in patients with various diseases
US3873683A (en) Pregnancy test composition and method
US4746731A (en) Isolated tissue protein PP18
US4705748A (en) Antigen associated with early detection of mammalian pregnancy
EP0221561A2 (fr) Antigène indicateur de cancer du sein humain et essais basés sur son usage
AU679743B2 (en) Tumor marker control
Wåhlstrand et al. A radioimmunosorbent technique for the assay of B-and C-types of carbonic anhydrase in human tissues
CA2164666A1 (fr) Controle de marqueurs tumoraux
IE67563B1 (en) A process for the isolation of basement membrane proteins from human and animal tissues
Schultz et al. Measurement of α-lactalbumin in serum and mammary tumors of rats by radioimmunoassay
US6767709B1 (en) Immunoassay of human medullasin and diagnosis of multiple sclerosis using the same
JP2003516543A (ja) アッセイ
Toshiyuki et al. Purification, characterization and development of radioimmunoassay of human liver ribonuclease
Van Oost et al. Measurement of ferritin in serum: application in diagnostic use
EP0504423A1 (fr) Procede et kit pour l'nalyse immunologique du propeptide de l'osteocalcine et de la pro-osteocalcine
CA1132044A (fr) ANALYSE DE .alpha..SUB.2-GLYCOPROTEINE D'OPSONISATION PAR AGGLUTINATION DIRECTE

Legal Events

Date Code Title Description
FZDE Discontinued